Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer

Clinical trial NCT00496795 · UNKNOWN

Trial details

NCT number: NCT00496795
Sponsor: University of Bergen
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Stage III Breast Cancer AJCC V7

Start date: 2007-09-01
Primary completion: 2016-05-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.